Clima Social Familiar y Adaptación de conducta en estudiantes de Secundaria de una Institución Educativa Privada de Trujillo

El clima social familiar y adaptación de conducta en estudiantes de secundaria de una institución educativa privada de Trujillo. La población que se tuvo fueron 120 personas, estudiantes, del 4to y 5to grado de educación secundaria, cuyas características etarias iban entre los 15 y 17 años, los instrumentos psicométricos utilizados fueron la Escala de Clima Social Familiar (FES) y el Inventario Adaptación de Conducta (IAC) Al finalizar el estudio evidencia, que existe una predominancia del nivel medio a nivel general y en las dimensiones Relaciones y Desarrollo, con porcentajes que oscilan entre 39.2% y 44.2%. Asimismo, se evidencia un nivel bajo en la dimensión Estabilidad, representado por el 43.3%. Por otro lado, en el nivel medio de Adaptación de Conducta, a nivel general y en sus dimensiones indican porcentajes que oscilan entre 35.8% y 48.3%. En cuanto al análisis relacional, se encontró una correlación muy significativa, positiva y en grado medio, entre Clima Social Familiar y Adaptación de Conducta en los sujetos de estudio.Family social climate and behavior adaptation in high school students from a private educational institution in Trujillo. The population that was had was 120 people, students, of the 4th and 5th grade of secondary education, whose age characteristics were between 15 and 17 years old, the psychometric instruments used were the Family Social Climate Scale (FES) and the Inventory Adaptation of Conduct (IAC) At the end of the study, it shows that there is a predominance of the middle level at a general level and in the Relationships and Development dimensions, with percentages that range between 39.2% and 44.2%. Likewise, a low level is evidenced in the Stability dimension, represented by 43.3%. On the other hand, at the medium level of Behavior Adaptation, at a general level and in its dimensions, they indicate percentages that range between 35.8% and 48.3%. Regarding the relational analysis, a very significant, positive and medium-degree correlation was found between Family Social Climate and Behavior Adaptation in the study subjects.Tesi

Risk of COVID-19 after natural infection or vaccinationResearch in context

Summary: Background: While vaccines have established utility against COVID-19, phase 3 efficacy studies have generally not comprehensively evaluated protection provided by previous infection or hybrid immunity (previous infection plus vaccination). Individual patient data from US government-supported harmonized vaccine trials provide an unprecedented sample population to address this issue. We characterized the protective efficacy of previous SARS-CoV-2 infection and hybrid immunity against COVID-19 early in the pandemic over three-to six-month follow-up and compared with vaccine-associated protection. Methods: In this post-hoc cross-protocol analysis of the Moderna, AstraZeneca, Janssen, and Novavax COVID-19 vaccine clinical trials, we allocated participants into four groups based on previous-infection status at enrolment and treatment: no previous infection/placebo; previous infection/placebo; no previous infection/vaccine; and previous infection/vaccine. The main outcome was RT-PCR-confirmed COVID-19 >7–15 days (per original protocols) after final study injection. We calculated crude and adjusted efficacy measures. Findings: Previous infection/placebo participants had a 92% decreased risk of future COVID-19 compared to no previous infection/placebo participants (overall hazard ratio [HR] ratio: 0.08; 95% CI: 0.05–0.13). Among single-dose Janssen participants, hybrid immunity conferred greater protection than vaccine alone (HR: 0.03; 95% CI: 0.01–0.10). Too few infections were observed to draw statistical inferences comparing hybrid immunity to vaccine alone for other trials. Vaccination, previous infection, and hybrid immunity all provided near-complete protection against severe disease. Interpretation: Previous infection, any hybrid immunity, and two-dose vaccination all provided substantial protection against symptomatic and severe COVID-19 through the early Delta period. Thus, as a surrogate for natural infection, vaccination remains the safest approach to protection. Funding: National Institutes of Health

Risk of COVID-19 after natural infection or vaccinationResearch in context

Background: While vaccines have established utility against COVID-19, phase 3 efficacy studies have generally not comprehensively evaluated protection provided by previous infection or hybrid immunity (previous infection plus vaccination). Individual patient data from US government-supported harmonized vaccine trials provide an unprecedented sample population to address this issue. We characterized the protective efficacy of previous SARS-CoV-2 infection and hybrid immunity against COVID-19 early in the pandemic over three-to six-month follow-up and compared with vaccine-associated protection. Methods: In this post-hoc cross-protocol analysis of the Moderna, AstraZeneca, Janssen, and Novavax COVID-19 vaccine clinical trials, we allocated participants into four groups based on previous-infection status at enrolment and treatment: no previous infection/placebo; previous infection/placebo; no previous infection/vaccine; and previous infection/vaccine. The main outcome was RT-PCR-confirmed COVID-19 >7–15 days (per original protocols) after final study injection. We calculated crude and adjusted efficacy measures. Findings: Previous infection/placebo participants had a 92% decreased risk of future COVID-19 compared to no previous infection/placebo participants (overall hazard ratio [HR] ratio: 0.08; 95% CI: 0.05–0.13). Among single-dose Janssen participants, hybrid immunity conferred greater protection than vaccine alone (HR: 0.03; 95% CI: 0.01–0.10). Too few infections were observed to draw statistical inferences comparing hybrid immunity to vaccine alone for other trials. Vaccination, previous infection, and hybrid immunity all provided near-complete protection against severe disease. Interpretation: Previous infection, any hybrid immunity, and two-dose vaccination all provided substantial protection against symptomatic and severe COVID-19 through the early Delta period. Thus, as a surrogate for natural infection, vaccination remains the safest approach to protection. Funding: National Institutes of Health